|
Access Pharmaceuticals, Inc. - Company Profile Snapshot
| Company Profile: |
Access Pharmaceuticals, Inc. |
| Ticker: |
ACCPE |
| Exchanges: |
OTC |
| 2008 Sales: |
291,000 |
| Major Industry: |
Miscellaneous |
| Sub Industry: |
Medical Services |
| Country: |
UNITED STATES |
| Employees: |
9 |
Business Description
Access Pharmaceuticals, Inc.. The Group's principal activity is to develop drug delivery systems and advanced polymer technology for application in cancer treatment, dermatology and treatment of oral diseases. It is in the development stage. The Group has proprietary patents and rights to seven drug delivery technology platforms: synthetic polymer targeted delivery, vitamin mediated targeted delivery (including oral), bioerodible hydrogel technology, nanoparticles and nanoparticle networks, Residerm (R) topical delivery, carbohydrate targeting technology and agents for the prevention and treatment of viral disease, including HIV. The products Residerm (R) A gel - Zindaclin (TM), Aphthasol (R) and Aptheal (R) are being marketed currently. On 25-February-2009, the Group acquired MacroChem Corporation.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
